Attitude of Japanese palliative care specialists towards adjuvant analgesics cancer-related neuropathic pain refractory to opioid therapy: a nationwide cross-sectional survey.
Attitude of Japanese palliative care specialists towards adjuvant analgesics cancer-related neuropathic pain refractory to opioid therapy: a nationwide cross-sectional survey.
复制标题
日本姑息治疗专家对阿片类药物治疗难治性癌症相关神经病理性疼痛的辅助镇痛药的态度：一项全国性横断面调查。
DOI：
10.1093/jjco/hyz002
复制
发表时间：
2019
期刊：
影响因子：
2.4
通讯作者：
Koyama A.
中科院分区：
文献类型：
--
作者：
Matsuoka H;Tagami K;Ariyoshi K;Oyamada S;Kizawa Y;Inoue A;Koyama A.
癌症相关神经性疼痛（CNP）需要多种药物治疗，包括抗惊厥药和抗抑郁药；然而，支持这种做法的有力证据是有限的。本研究为横断面问卷调查。由于阿片类药物治疗难治性CNP的辅助镇痛药标准剂量尚不明确，本研究的目的是澄清专家对阿片类药物治疗难治性CNP患者使用度洛西汀和普瑞巴林的意见。调查了288名认证的姑息治疗专家，共分析了87份（42%）回复。25%的专家考虑将度洛西汀剂量增加至60mg /天，58%的专家考虑将普瑞巴林剂量增加至300mg /天，用于阿片类药物治疗难治的CNP。然而，23%的专家成功地将度洛西汀剂量增加到60毫克/天，17%的专家成功地将普瑞巴林剂量增加到300毫克/天。
Cancer-related neuropathic pain (CNP) requires therapy involving multiple pharmaceuticals, including anticonvulsants and antidepressants; however, strong evidence to support this practice is limited. This study is a cross-sectional questionnaire-based survey. As the standard dose of adjuvant analgesics for CNP refractory to opioid therapy is not clear, the purpose of this study is to clarify the opinions of specialists about the usage of duloxetine and pregabalin for patients with CNP refractory to opioid therapy. Two hundred and eight certified palliative care specialists were surveyed and a total of 87 (42%) responses were analyzed. Twenty-five percent of specialists had considered increasing duloxetine doses up to 60 mg/day and 58% had considered increasing pregabalin doses up to 300 mg/day for CNP refractory to opioid therapy. However, 23% of the specialists succeeded in increasing duloxetine doses up to 60 mg/day and 17% in increasing pregabalin doses up to 300 mg/day, respectively.